Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Has Average Target Price of $202.59 According to Analysts

Neurocrine Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly positive: Neurocrine Biosciences has a “Moderate Buy” consensus from 24 analysts—19 buy ratings, one strong buy and four holds—with an average 12-month price target of $202.59.
  • Quarterly results beat estimates: The company reported EPS of $3.29 versus the $1.91 consensus and revenue of $1.12 billion versus $1.04 billion expected; revenue rose 41.3% year over year.
  • Insiders have been selling shares: Company insiders sold 18,137 shares worth about $2.83 million over the past three months. The reported sales were made under pre-arranged trading plans.
  • Five stocks to consider instead of Neurocrine Biosciences.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-four research firms that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $202.59.

NBIX has been the subject of several research analyst reports. Citigroup raised their target price on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the company a "buy" rating in a research note on Thursday, September 3rd. Weiss Ratings upgraded shares of Neurocrine Biosciences from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 14th. BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a "market perform" rating on the stock in a research note on Monday, October 12th. Wedbush boosted their price target on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an "outperform" rating in a research note on Monday, August 3rd. Finally, Zacks Research lowered Neurocrine Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 4th.

View Our Latest Analysis on NBIX

Neurocrine Biosciences Trading Down 3.8%

NASDAQ NBIX opened at $150.57 on Friday. Neurocrine Biosciences has a 12 month low of $122.14 and a 12 month high of $186.12. The stock has a market cap of $15.24 billion, a PE ratio of 22.34, a P/E/G ratio of 0.67 and a beta of 0.36. The stock's 50 day moving average is $149.03 and its 200 day moving average is $149.49.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the firm posted $2.04 EPS. The company's revenue was up 41.3% on a year-over-year basis. On average, analysts forecast that Neurocrine Biosciences will post 8.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares of the company's stock, valued at approximately $6,729,417.60. This represents a 5.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,200 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the transaction, the director owned 10,386 shares of the company's stock, valued at $1,727,918.82. This represents a 40.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 18,137 shares of company stock worth $2,829,332. Corporate insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NBIX. BlackRock Inc. purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $2,310,886,000. Aberdeen Group plc increased its stake in Neurocrine Biosciences by 5,055.5% during the 3rd quarter. Aberdeen Group plc now owns 1,183,444 shares of the company's stock valued at $167,860,000 after purchasing an additional 1,160,489 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at $117,827,000. Ieq Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $107,914,000. Finally, Bank of America Corp DE acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth about $104,382,000. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

Featured Articles

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Neurocrine Biosciences Right Now?

Before you consider Neurocrine Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.

While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines